Revance Therapeutics, Inc. (50)

Browse by Contract Category

Contracts

Second Amendment to Exclusive Distribution Agreement, dated November 18, 2020, by and between Revance Therapeutics, Inc. and Teoxane SA (Filed With SEC on November 8, 2022)
Underwriting Agreement, dated September 12, 2022, by and among the Company and the Underwriters (Filed With SEC on September 14, 2022)
Third Addendum to License and Service Agreement dated December 9, 2021 between Revance Therapeutics, Inc. and List E, LLC (Filed With SEC on May 10, 2022)
Separation Agreement dated February 25, 2022 by and between Revance Therapeutics, Inc. and Abhay Joshi (Filed With SEC on May 10, 2022)
Description of Registrants Securities (Filed With SEC on February 28, 2022)
Second Amendment to Lease, dated July 1, 2021 by and between Revance Therapeutics, Inc and 1222 Demonbreun, LP (Filed With SEC on November 9, 2021)
Note Purchase Agreement dated March 18, 2022 among Revance Therapeutics, Inc., certain subsidiaries of Revance Therapeutics, Inc., Athyrium Buffalo LP and the purchasers from time... (Filed With SEC on May 10, 2022)
Separation Agreement (Filed With SEC on February 28, 2022)
Technology Transfer, Validation and Commercial Fill/Finish Services Agreement dated March 14, 2017 between Revance Therapeutics, Inc. and Ajinomoto Althea, Inc (Filed With SEC on February 28, 2022)
Revance Therapeutics, Inc. 2022 Management Bonus Plan (Filed With SEC on February 28, 2022)
Commercial Supply Agreement, effective as of April 6, 2021, by and between Revance Therapeutics, Inc. and Lyophilization Services of New England, Inc (Filed With SEC on August 5, 2021)
Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 10, 2021)
Second Addendum to License and Service Agreement, dated March 2, 2021 between Revance Therapeutics, Inc. and List Biological Laboratories, Inc (Filed With SEC on May 10, 2021)
Letter Amendment to the License Agreement dated January 8, 2020 by and between Revance Therapeutics, Inc. and Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd (Filed With SEC on February 25, 2021)
Amendment No. 1 to the Technology Transfer, Validation and Commercial Fill/Finish Services Agreement dated December 18, 2020 between Revance Therapeutics, Inc. and Ajinomoto... (Filed With SEC on February 25, 2021)
Revance Therapeutics, Inc. 2021 Management Bonus Plan (Filed With SEC on February 25, 2021)
Amendment to Lease, effective as of January 4, 2021, by and between Revance Therapeutics, Inc. and 1222 Demonbreun, LP (Filed With SEC on February 25, 2021)
Form of Restricted Stock Agreement and Grant Notice under Amended and Restated Revance Therapeutics, Inc. 2014 Inducement Plan (Filed With SEC on February 25, 2021)
Form of Restricted Stock Bonus Agreement and Grant Notice for Revance Therapeutics, Inc. 2014 Equity Incentive Plan (Filed With SEC on February 25, 2021)
Description of Registrants Securities (Filed With SEC on February 25, 2021)
Office Lease Agreement dated November 19, 2020 (Filed With SEC on November 20, 2020)
Executive Employment Agreement effective July 23, 2020 by and between Revance Therapeutics, Inc. and Aubrey Rankin (Filed With SEC on November 9, 2020)
First Amendment to Exclusive Distribution Agreement (Filed With SEC on November 9, 2020)
Revance Therapeutics, Inc. Amended and Restated 2014 Inducement Plan (Filed With SEC on November 9, 2020)
Fifth Amendment to Lease, dated July 1, 2020, by and between Revance Therapeutics, Inc. and BMR-Pacific Research Center LP (Filed With SEC on August 6, 2020)
Form of Lock-Up Agreement by and between Revance Therapeutics, Inc. and each of the parties named in each agreement therein (Filed With SEC on June 10, 2020)
Form of Voting Agreement by and between Revance Therapeutics, Inc. and each of the parties named in each agreement therein (Filed With SEC on June 10, 2020)
Loan Agreement, dated May 18, 2020, by and between Revance Therapeutics, Inc. and Hint, Inc (Filed With SEC on June 10, 2020)
Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 26, 2020)
Description of Registrants Securities (Filed With SEC on February 26, 2020)
Exclusive Distribution Agreement, dated January 10, 2020, by and between Revance Therapeutics, Inc. and Teoxane SA (Filed With SEC on February 26, 2020)
Executive Employment Agreement dated February 17, 2020 by and between Revance Therapeutics, Inc. and Dwight Moxie (Filed With SEC on February 26, 2020)
Separation Agreement effective January 8, 2020 by and between Revance Therapeutics, Inc. and Caryn G. McDowell (Filed With SEC on February 26, 2020)
Executive Employment Agreement effective December 1, 2019 and between Revance Therapeutics, Inc. and Dustin Sjuts (Filed With SEC on February 26, 2020)
Revance Therapeutics, Inc. 2020 Management Bonus Plan (Filed With SEC on February 26, 2020)
Indenture, dated as of February 14, 2020, by and between Revance Therapeutics, Inc. and U.S. Bank National Association, as Trustee (Filed With SEC on February 14, 2020)
Underwriting Agreement, dated December 4, 2019, by and among the Company and the Underwriters (Filed With SEC on December 4, 2019)
Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on November 4, 2019)
Executive Employment Agreement effective October 13, 2019 by and between Revance Therapeutics, Inc. and Mark J. Foley (Filed With SEC on November 4, 2019)
Revance Therapeutics, Inc. Executive Severance Benefit Plan, Amended and Restated effective October 13, 2019 (Filed With SEC on November 4, 2019)
Separation Agreement effective October 11, 2019 by and between Revance Therapeutics, Inc. and L. Daniel Browne (Filed With SEC on November 4, 2019)
Amendment #1 to the Collaboration and License Agreement dated August 22, 2019 between Revance Therapeutics, Inc. and Mylan Ireland Ltd (Filed With SEC on November 4, 2019)
Revance Therapeutics, Inc. Executive Severance Benefit Plan, Amended and Restated Effective February 12, 2019 (Filed With SEC on May 9, 2019)
Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 9, 2019)
Employment Agreement dated November 7, 2018 by and between Revance Therapeutics, Inc. and Cyril Allouche (Filed With SEC on February 28, 2019)
Executive Employment Agreement dated November 5, 2018 by and between Revance Therapeutics, Inc. and Tobin Schilke (Filed With SEC on February 28, 2019)
Revance Therapeutics, Inc. 2019 Management Bonus Plan (Filed With SEC on February 28, 2019)
License Agreement, dated December 4, 2018, by and between Revance Therapeutics, Inc. and Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd (Filed With SEC on February 28, 2019)
Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 28, 2019)
Underwriting Agreement, dated January 16, 2019, by and among the Company and the Underwriters (Filed With SEC on January 17, 2019)